Janet E. Reed

Janet E. Reed — Potter Anderson & Corroon LLP (Wilmington, DE)

Focus areas. Reed's practice is centered on life sciences and biotechnology patents rather than standards-based or mechanical/software work. Firm and IAM Patent 1000 materials describe her as the firm's life sciences lead, handling patents in medicine, agriculture and food, with a technical background in recombinant DNA, gene expression, cell biology, immunology, microbiology and plant pathology. Her practice emphasis is prosecution, patent portfolio management, licensing/commercialization agreements, due diligence and patentability/infringement/freedom-to-operate opinions — she holds a Ph.D. in biochemistry and USPTO registration, and worked in a laboratory setting before entering law. Her single tracked litigation matter fits that profile: nucleic acid target-enrichment and next-generation sequencing technology.

Side preference. The tracked data show only one appearance, on the defendant side (0 plaintiff / 1 defendant). Consistent with her prosecution-and-counseling orientation and Potter Anderson's role as a Delaware defense/local-counsel firm, there is no evidence of plaintiff-side or NPE/PAE enforcement work; the record is too thin to characterize a durable side preference beyond the fact that her only tracked litigation appearance was defensive.

Firm context. She is at Potter Anderson & Corroon, where she has been a partner and head of the firm's intellectual property transactional and counseling practice; the firm bio now describes her as the "former head" of that practice, and the tracked docket lists her as Of Counsel. Public directories still list her as a partner, so the current title is not fully consistent across sources. No prior law firm appears reliably in the searchable record; her earlier career included graduate research and a visiting postdoctoral research position at DuPont.

Notable case. Tecan Genomics, Inc. v. QIAGEN Sciences, LLC et al., No. 1:23-cv-01115-GBW (D. Del., filed Oct. 6, 2023), in which Tecan (formerly NuGEN Technologies) asserts U.S. Patent Nos. 10,036,012; 10,876,108; 11,098,357; and 11,725,241 against QIAGEN entities over QIAseq target-enrichment/NGS products, with willfulness allegations tied to QIAGEN's 2013 due diligence on NuGEN. Reed appears for the QIAGEN defendants. A parallel case against Invitae/ArcherDx/IDT (No. 1:23-cv-01114) involves overlapping patents. No verdict, settlement or appellate outcome is verifiable as of this writing.

PTAB / IPR experience. Related PTAB proceedings exist — QIAGEN filed IPR2025-00026, -00027, -00028 and -00029 against the asserted Tecan patents, and IDT filed a separate set (IPR2024-01502, -01504, -01506, IPR2025-00015, -00016) in the parallel matter, with Tecan seeking Director Review on discretionary-denial grounds. However, I found no source confirming Reed personally as counsel of record in those IPRs, so her individual PTAB experience is not verified; she should not be described as a regular IPR practitioner on this record.

Bar / education (as sourced). J.D., Rutgers School of Law, with honors, 1993 (Board of Editors, Rutgers Law Journal); Ph.D., Rutgers, 1988; M.S., University of Nebraska–Lincoln, 1982; B.A., Sonoma State University, 1979. Admitted in Pennsylvania (1993), New Jersey (1995), Delaware (2009) and before the USPTO (1992).